Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
Published: 03 December 2019
-
Views:
518 -
Likes:
7
-
Views:
518 -
Likes:
7
-
9m 54sPart 1 SGLT2 in HF Now and the Future Andrew JS Coats, Carolyn Lam
-
5m 9sPart 2 DAPA-HF Trial Design Rationale Felipe Martínez
-
8m 5sPart 3 SGLT2 beyond diabetes Lars H Lund
-
10m 15sPart 4 Guidelines, Recent Data & Future Practices Andrew JS Coats, Scott Solomon
-
5m 18sPart 5 DAPA-HF Trial Frank Ruschitzka
Overview
The opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF). Although the exact mechanisms of cardiovascular (CV) benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.
Recent trials — including the recently presented DAPA-HF — have provided further insight into the effectiveness of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the absence of T2DM.
Learning Objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data; differentiate the latest guideline updates for the treatment of T2D
- Consider comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF)
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF
- Assess the interrelationships linking diabetes, HF and CVD
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
More from this programme
Part 1
SGLT2 in HF Now and the Future
1 session | |
SGLT2 in HF Now and the Future | Watch now |
Part 2
DAPA-HF Trial Design Rationale
1 session | |
DAPA-HF Trial Design Rationale | Watch now |
Part 3
SGLT2 beyond diabetes
1 session | |
SGLT2 beyond diabetes | Watch now |
Part 4
Guidelines, Recent Data & Future Practices
Part 5
DAPA-HF Trial
1 session | |
DAPA-HF Trial | Watch now |
Part 6
Discussion with the DAPA-HF Trialist
Faculty Biographies
John JV McMurray
Professor of Cardiology
Prof John McMurray is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. A graduate of Manchester University, Prof McMurray completed postgraduate research at the University of Dundee.
Prof McMurray is a Fellow of the European Society of Cardiology (ESC), American College of Cardiology and American Heart Association as well as the medical Royal Colleges in Edinburgh and Glasgow and the Royal Society of Edinburgh and UK Academy of Medical Sciences.
Mikhail Kosiborod
Cardiologist
Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.